menu
    • menu
    [{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Curadev Pharma Private Limited","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Curadev Pharma Private Limited \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"Curadev Pharma Private Limited \/ Bayer"},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CRD3874-SI","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Curadev Pharma Private Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curadev Pharma Private Limited \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curadev Pharma Private Limited \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Curadev Pharma Private Limited

    Menu

    Curadev Pharma Private Limited

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Curadev Pharma Private Limited

                            India arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Curadev Pharma Private Limited

                            India arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRD3874-SI

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curadev Completes First Treatment Cycle in STING Agonist Trial

                            Details : CRD3874-SI targets STimulator of INterferon Genes to activate immune cells for tumor eradication and is being evaluated for sarcoma.

                            Brand Name : CRD3874-SI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 27, 2024

                            Lead Product(s) : CRD3874-SI

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Curadev Pharma Private Limited

                            India arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Curadev Pharma Private Limited

                            India arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : Bayer AG

                            Deal Size : $270.4 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across ...

                            Details : The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 23, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : Bayer AG

                            Deal Size : $270.4 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth